Testosterone Cypionate TRT Guide: Dosing, Draw Volumes & the Bloodwork That Matters
Testosterone cypionate is the backbone of TRT in North America — an 80-year-old medicine with modern trial data behind it. This guide covers the protocols people actually run, why twice-weekly replaced the old label schedule, the draw math for every concentration, and the short list of numbers on a blood panel that decide whether a protocol is working or quietly causing problems.
Also known as Depo-Testosterone, Test Cyp
Testosterone Cypionate quick start
- Route
- Intramuscular or subcutaneous injection — SubQ with an insulin syringe has become a community standard for TRT doses: steadier levels reported, less scar tissue, easier self-administration. Supplied pre-mixed in oil; nothing to reconstitute.
- Dose context
- 100–200 mg per week for male TRT, almost always split into two or more injections. Where it lands inside that range is set by bloodwork and symptoms, not by ambition. Women's testosterone therapy is a different universe: roughly a tenth of the dose, usually daily cream — see the For Women section.
- Measure
- At the common 200 mg/mL concentration, a 100 mg dose is 0.5 mL — 50 units on a U-100 syringe. Always check YOUR vial: 100, 200 and 250 mg/mL all circulate.
- Cycle context
- TRT is not cycled — it is continuous, because it replaces what your own (suppressed) production no longer supplies. Stopping means a recovery phase, not just an off-cycle.
- Status
- FDA-approved prescription medicine, and a DEA Schedule III controlled substance — possession without a prescription is a federal offence.
Dosing context and schedule
What follows is drawn from the published record and from what the community has settled on. Reference points, not prescriptions — your situation is yours.
| Phase | Dose | Volume | Units (U-100) | Note |
|---|---|---|---|---|
| Typical starting protocol | 120–140 mg/week | 0.30–0.35 mL × 2 | 30–35 units twice weekly | At 200 mg/mL, split Monday/Thursday. Labs at 6–8 weeks decide the adjustment. |
| Common maintenance range | 100–200 mg/week | 0.25–0.50 mL × 2 | 25–50 units twice weekly | Most men settle here. More is not better once levels and symptoms agree. |
| Older label schedule | 200 mg every 2 weeks | 1.0 mL | — | The historical clinic pattern. Produces a peak-and-trough rollercoaster most protocols have abandoned. |
Cycle structures
| Approach | Duration | Review point | Note |
|---|---|---|---|
| Twice-weekly split | Continuous | Labs at 6–8 weeks, then every 6–12 months | The community and modern-clinic standard. With an 8-day half-life, two injections a week keeps levels within a narrow band. |
| Every-other-day microdosing | Continuous | Same lab schedule | Flattest possible curve; chosen by people sensitive to peaks (mood, estradiol symptoms, hematocrit). |
| Weekly single injection | Continuous | Same lab schedule | Workable and common, with a noticeable end-of-week dip for some. |
For women
What people actually run
The converged protocol
100–160 mg/week, split into two SubQ injections with an insulin syringe, trough bloodwork at 6–8 weeks, and adjust by symptoms plus labs together — never labs alone. HCG alongside if fertility or testicular atrophy matters. No AI unless estradiol symptoms are real and persistent.
The great community migration of the last decade is from big infrequent IM shots to small frequent SubQ ones. Twice weekly or every other day keeps blood levels inside a narrow band, which people consistently report as steadier mood and energy, fewer estradiol swings, and often a lower total dose achieving the same trough.
The estradiol lesson took the community years to learn: high-normal estradiol on TRT is usually fine and protective, and reflexively crushing it with anastrozole causes more harm (joints, lipids, mood, libido) than the number ever did. The settled position: treat persistent symptoms, not lab values in isolation.
Fertility is the conversation to have BEFORE the first injection, not after. Exogenous testosterone shuts down the signalling that drives both sperm production and natural testosterone; HCG run alongside preserves much of it. Recovery after long unassisted use is slow and not guaranteed.
Hematocrit is the number that quietly ends protocols. Testosterone raises red blood cell production; SubQ dosing and lower peaks blunt it, hydrating before the blood draw avoids false alarms, and a genuinely rising trend means dose review — donation is a stopgap the community over-relies on.
What the evidence actually says
The honest picture
Testosterone therapy for genuinely low testosterone is settled medicine backed by decades of use and, since 2023, a proper cardiovascular outcomes trial: TRAVERSE randomised over 5,000 middle-aged and older men with hypogonadism and elevated cardiac risk, and found no increase in major cardiovascular events versus placebo. That result ended the biggest safety argument of the previous decade — with honest footnotes: the trial did note small increases in atrial fibrillation, acute kidney injury and pulmonary embolism, and it studied gels at replacement doses, not injections at whatever dose a men's-clinic marketing funnel lands on.
Where the evidence actually runs out: "low-normal levels plus vague symptoms" — the fastest-growing TRT demographic — was not what the trials studied, and benefit there is much less certain than the clinics imply. Supraphysiologic dosing for physique is pharmacology with a different risk ledger entirely and no therapeutic trial base. And the twice-weekly SubQ protocols the community prefers are supported by pharmacokinetic logic and consistent experience rather than outcome trials — almost certainly fine, honestly still uncharacterised.
How it is proposed to work
Testosterone cypionate is testosterone with a fatty-acid ester attached. The ester does nothing biologically — it exists to slow release from the injection depot, stretching a hormone with a short natural half-life into a ~8-day injectable. Once cleaved, what circulates is simply testosterone.
From there the biology is the familiar androgen story: receptor binding in muscle, bone, brain, marrow and skin; aromatisation of a fraction into estradiol (which men need — it drives much of the bone, joint, lipid and libido benefit); and 5α-reduction into DHT in skin and prostate.
The same signal that replaces testosterone also tells the pituitary to stop asking for it: LH and FSH fall, and with them natural production and sperm output. This is not a side effect; it is the mechanism working as designed — and it is why fertility planning belongs before the first injection.
When to talk to a doctor first
Most people run Testosterone Cypionate without incident. These are the specific situations where it is worth a conversation with a clinician before you start — not reasons to rule it out, but reasons to go in with your eyes open.
- Without a prescription — beyond the legal exposure, unsupervised testosterone means nobody is watching hematocrit, estradiol or your prostate. Legitimate TRT is accessible in 2026; the grey market solves a problem that mostly no longer exists.
- Prostate or male breast cancer, active or suspected — absolute contraindications on the label.
- If you want children soon and are not running fertility support — suppression of sperm production starts immediately and recovery is slow. Bank sperm or add HCG first; do not discover this after.
- Untreated severe sleep apnea — testosterone can worsen it, and the fatigue that brought you in may BE apnea wearing a low-T costume.
- Hematocrit already at the top of range — sort that out first, or the protocol ends itself by week 12.
- Under 25 with normal levels — you would be trading a working HPTA for a number you already have, plus a fertility problem you did not.
What to expect
Most of what people notice is mild and settles within the first week or two. The list below is ordered by how often it actually comes up, so you know what is routine and what is worth paying attention to.
Common, and usually settles
- Testicular atrophy and reduced sperm output — mechanism, not accident; HCG alongside mitigates it.
- Acne and oilier skin, most in the first months.
- Rising hematocrit — the number to actually watch.
- Injection site irritation; more with high-concentration oils.
Less common
- Estradiol-related symptoms — moodiness, water retention, nipple sensitivity — usually a dose-shape problem solved with smaller, more frequent injections before any AI.
- Accelerated male-pattern hair loss in the genetically disposed.
- Mood edge or irritability at trough or peak — flattens with dosing frequency.
- Blood pressure drift upward.
Rare — stop and get advice
- Erythrocytosis — hematocrit high enough to raise clot risk. This is the common serious one, and it is fully monitorable.
- Venous thromboembolism — leg swelling/pain or sudden breathlessness is an emergency.
- Gynecomastia — breast tissue growth from unmanaged estradiol elevation; address early, not late.
- Worsened sleep apnea. And per TRAVERSE: small excesses of atrial fibrillation, kidney injury and pulmonary embolism versus placebo — real, rare, and part of the honest ledger.
Known interactions
Interactions involving Testosterone Cypionate's drug class that DoseIQ screens for. Each one cites where it comes from — an FDA label section or the published record — because an interaction warning you can't trace is just noise.
Androgens increase warfarin's effect; INR can climb after starting or raising testosterone.
What to do: Tell the prescriber managing your warfarin about the testosterone — INR gets checked more often around any dose change.
Source: FDA label, testosterone products §7
Spironolactone blocks androgen receptors — it works directly against TRT's purpose.
What to do: Sometimes intentional (acne dosing is low); worth confirming the prescribers know about each other.
Source: Spironolactone pharmacology
They block conversion of testosterone to DHT — usually the deliberate point (hair), but it changes what a given T dose does.
What to do: Nothing to do if intentional; PSA readings run ~half their true value on these, which the Markers page notes.
Source: FDA labels, finasteride/dutasteride
How much to draw
Testosterone Cypionate comes ready to use in oil, so there is nothing to mix. The only thing that matters is the concentration printed on your vial — the same 1 mL can be 100 mg or 250 mg. Check the label before you draw.
| Concentration on the vial | 100mg | 200mg |
|---|---|---|
| 200 mg/mL (most common) | 0.50 mL 50 units | 1.00 mL 100 units |
| 100 mg/mL | 1.00 mL 100 units | 2.00 mL 200 units |
| 250 mg/mL | 0.40 mL 40 units | 0.80 mL 80 units |
Timeline and monitoring
- Weeks 1–3Libido and morning erections often move first. Blood levels reach steady state around week 4–5.
- Weeks 4–8Energy, mood and drive changes consolidate. First labs at 6–8 weeks — trough, drawn the morning of an injection day, before injecting.
- Months 3–6Body-composition changes become visible with training. Estradiol and hematocrit find their new baseline — second labs here.
- Month 6 onwardSteady state. Labs every 6–12 months: testosterone, estradiol, hematocrit, PSA (age-appropriate), lipids.
Bloodwork worth discussing
Markers a clinician may consider relevant before or during a protocol. This is context for a conversation, not a self-ordering list.
| Marker | Why it is relevant |
|---|---|
| Total and free testosterone (trough) | The dose dial. Drawn at trough so results are comparable protocol to protocol. |
| Hematocrit / hemoglobin | THE safety number on TRT. Rising trend = dose or frequency review before it forces a stop. |
| Estradiol (sensitive assay) | Interpreted alongside symptoms, never treated in isolation. |
| PSA | Age-appropriate baseline and monitoring per the label — an unexplained rise gets urology, not a shrug. |
| LH and FSH (before starting) | Only measurable before — they collapse on therapy, and their pre-TRT values say whether the problem is testes or signalling. |
| Lipids, HbA1c, blood pressure | The metabolic context TRT lives in. |
Supplies by cycle length
A 10 mL vial at 200 mg/mL holds 2,000 mg — about 14 weeks at 140 mg/week. Multi-dose vials with preserved oil are drawn from repeatedly.
| Cycle length | Vials | Syringes | BAC water | Planning note |
|---|---|---|---|---|
| 12 weeks at 140 mg/week | 1 × 10 mL (200 mg/mL) | 24 draws + injection needles | None — pre-mixed oil | Draw with 18–21 g, inject with 25–29 g. SubQ users often draw and inject with the same 27–29 g insulin syringe, slowly. |
| 6 months at 140 mg/week | 2 × 10 mL | 52 draws | None | Alcohol swabs for the stopper every draw — the vial gets punctured ~50 times. |
What the research record contains
TRAVERSE (NEJM, 2023, n≈5,200): testosterone therapy in hypogonadal men at elevated cardiac risk showed no increase in major adverse cardiovascular events — the trial that settled the 2010s safety controversy — with small observed excesses in atrial fibrillation, acute kidney injury and pulmonary embolism.
The Testosterone Trials (TTrials, NEJM 2016): in older men with low testosterone, therapy produced moderate improvements in sexual function, mood and anemia; effects on vitality were smaller than hoped.
Decades of endocrinology practice support replacement for confirmed hypogonadism — two morning testosterone measurements plus symptoms, per Endocrine Society guidance — which is a different claim from the marketing around "optimisation".
The FDA updated class labelling after TRAVERSE, and testosterone remains Schedule III under the Anabolic Steroids Control Act.
Storage and handling
- Room temperature, dark — refrigeration is unnecessary and makes the oil harder to draw.
- If the oil crystallises in cold conditions, warming the vial in hands or briefly in warm water redissolves it harmlessly.
- Swab the stopper every draw; a multi-dose vial lives or dies on technique.
- Store prescription vials in original labelled packaging — a Schedule III substance in an unlabelled vial is a legal problem even with a valid prescription.
Troubleshooting
Labs look perfect but I feel no different.
Give it 12 weeks before judging — some effects are slow. If nothing moves by then, the honest possibilities are: your symptoms were never testosterone, or the target range is wrong for you. Both are prescriber conversations, not reasons to double the dose.
Hematocrit hit 53%.
Hydrate properly and retest first — dehydrated draws run high. If it is real: smaller more frequent doses, SubQ if you were IM, dose reduction, and donation as a bridge, in that order. A rising trend is a protocol-design signal, not a donation subscription.
Moody and puffy by day 6 on weekly shots.
Classic peak-trough estradiol swing. Split the same weekly milligrams into two or three injections before anyone reaches for an aromatase inhibitor.
The oil is painful for days after IM.
Try SubQ with an insulin syringe, inject slower, and check the concentration — 250 mg/mL preparations run harsher. Rotate sites regardless.
How do I come off?
Slowly, with a plan, and with a prescriber — natural production takes months to recover and sometimes needs pharmacological help (HCG, SERMs) to restart. Cold turkey after long use is a miserable and avoidable experience.
Regulatory status
FDA-approved for male hypogonadism (Depo-Testosterone and generics). Not approved for "low-normal optimisation", which is off-label territory.
DEA Schedule III under the Anabolic Steroids Control Act — prescription required; unauthorised possession or importation is a federal offence.
WADA-prohibited (S1, anabolic agents) at all times in tested sport.
Telehealth TRT clinics are a legitimate prescription channel; their commercial incentive to diagnose generously is worth keeping in view when reading their lab interpretations.
How it compares
| Compared with | Difference that matters |
|---|---|
| Testosterone enanthate | Pharmacologically near-identical half-life and interchangeable in practice; cypionate dominates US prescribing, enanthate elsewhere. Choosing between them is mostly choosing a supply chain. |
| Testosterone gels | What TRAVERSE actually studied. No needles and easy reversal, against daily application, transfer risk to partners and children, and absorption variability injections do not have. |
| Enclomiphene | Raises your own production by stimulating the pituitary — preserves fertility and testicular function, appeals to younger men, but symptom relief is less consistent than direct replacement. |
| HCG alongside | Not a comparison so much as a companion: preserves testicular function and fertility that testosterone alone suppresses. The standard adjunct where fatherhood is still on the table. |
Frequently asked questions
IM or SubQ?
For TRT doses, either works. SubQ has become the community favourite — insulin syringes, less scar tissue, steadier reported levels — and clinics increasingly prescribe it. Large volumes and high concentrations still favour IM.
What level should I target?
The one where symptoms resolve and safety markers stay clean — for most men a trough in the mid-to-upper normal range. Chasing a number at the top of the range because a forum said so is how hematocrit problems start.
Will I lose fertility?
Sperm production falls on testosterone, substantially and sometimes to zero. It usually recovers after stopping, but slowly and not always fully — the longer on, the slower back. HCG alongside preserves much of it. If children are in the plan, this is conversation one.
Do I need an estrogen blocker?
Probably not. Estradiol rises with testosterone and mostly should — it carries bone, joint, lipid and libido benefits. The community consensus after years of AI overuse: manage symptoms with dose shape first, and reserve anastrozole for persistent, real symptoms under prescriber guidance.
Is TRT safe for my heart?
TRAVERSE — over 5,000 men, randomised, placebo-controlled — found no excess in major cardiovascular events in hypogonadal men treated to replacement levels. It also found small increases in atrial fibrillation and clot-related events, and it says nothing about supraphysiologic dosing. That is the honest, complete answer.
What about women on testosterone?
Real therapy, different universe: roughly a tenth of male dosing, usually daily transdermal cream, targeted to stay inside female physiologic range. Male injection protocols cause virilization, some irreversible. The For Women section above has the specifics.
References
- TRAVERSE — Cardiovascular Safety of Testosterone-Replacement TherapyLincoff et al., New England Journal of Medicine, 2023
- The Testosterone Trials — Effects in Older Men with Low TestosteroneSnyder et al., New England Journal of Medicine, 2016
- Testosterone Therapy in Men with Hypogonadism — Clinical Practice GuidelineEndocrine Society
- Depo-Testosterone (testosterone cypionate) Prescribing InformationU.S. Food and Drug Administration label
This page is an educational research reference and is not medical advice. Testosterone Cypionate is a controlled substance requiring a prescription. Dose figures reflect the published record and what the community has converged on — starting points to weigh, not instructions. Consult a qualified healthcare provider before starting any protocol.